Serina Therapeutics, Inc. SER
Serina Therapeutics, Inc. (NYSE: SER) is a CNS/neurology/psychiatry drug developer. Its lead program, SER-252 (POZ-apomorphine), is in Phase 1 for advanced Parkinson's disease.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| SER-252 (POZ-apomorphine) | advanced Parkinson's disease (Phase 1b registrational study) | small molecule | Phase 1 |
| Other POZ-enabled CNS candidates (small molecule, RNA-based, ADC) | neurological diseases and other indications | unclear | Pre-clinical |
Recent results and decisions
- Dec 10, 2025clinical hold Serina submitted a complete response to the FDA full clinical hold letter (Nov 25, 2025) on SER-252 concerning trehalose excipient; hold not yet lifted.
On November 25, 2025, the FDA issued a formal full clinical hold letter specifying the information required to permit initiation of the planned Phase 1b registrational study, SER-252-1b.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.